- Report
- March 2023
- 117 Pages
Global
From €4761EUR$4,900USD£4,130GBP
- Report
- October 2022
- 113 Pages
Global
From €4154EUR$4,275USD£3,604GBP
€4615EUR$4,750USD£4,004GBP
- Clinical Trials
- May 2023
- 220 Pages
Global
From €2429EUR$2,500USD£2,107GBP
- Report
- May 2023
- 200 Pages
Global
From €3838EUR$3,950USD£3,330GBP
- Report
- January 2022
- 60 Pages
Global
From €3838EUR$3,950USD£3,330GBP
- Report
- January 2022
- 60 Pages
Global
From €3838EUR$3,950USD£3,330GBP
- Report
- January 2022
- 224 Pages
Global
From €6753EUR$6,950USD£5,858GBP
- Drug Pipelines
- January 2022
- 200 Pages
Global
From €7287EUR$7,500USD£6,322GBP
- Report
- January 2022
- 60 Pages
Global
From €3838EUR$3,950USD£3,330GBP
- Report
- January 2022
- 200 Pages
Global
From €7287EUR$7,500USD£6,322GBP
- Report
- January 2022
- 200 Pages
Global
From €7287EUR$7,500USD£6,322GBP
- Report
- January 2022
- 60 Pages
Global
From €3838EUR$3,950USD£3,330GBP
- Clinical Trials
- February 2020
- 106 Pages
Global
From €1943EUR$2,000USD£1,686GBP
- Clinical Trials
- February 2020
- 106 Pages
Global
From €1943EUR$2,000USD£1,686GBP
- Report
- May 2019
- 70 Pages
Global
From €2332EUR$2,400USD£2,023GBP
- Report
- May 2022
- 175 Pages
Global
From €4372EUR$4,500USD£3,793GBP
- Report
- May 2021
- 42 Pages
Global
€1281EUR$1,318USD£1,111GBP
- Report
- August 2022
Global
From €962EUR$990USD£834GBP
- Report
- March 2021
- 100 Pages
Global
From €4372EUR$4,500USD£3,793GBP
- Report
- May 2022
- 76 Pages
Global
From €3396EUR$3,495USD£2,946GBP
Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence.
The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more
